Clinical trial design and AI-powered biostatistical validation specialist, Opyl (ASX: OPL), has signed a service level agreement with leading full-service Contract Research Organisation (CRO) Avion.
The strategic collaboration further validates Opyl’s growing recognition and positive reception in the APAC region, as it follows successful partnerships with several well-known and highly respected CROs.
This upward trajectory demonstrates strong market validation of Opyl’s proprietary TrialKey platform and its value in transforming clinical trial design, execution, and success rates.
Key Highlights:
- Strategic Collaboration: The partnership combines Avion’s expertise in clinical trial management with Opyl’s proprietary TrialKey platform, delivering data-driven insights to optimise trial design and improve outcomes.
- Market Validation: Following partnerships with leading CROs in APAC, this agreement highlights growing recognition of Opyl’s innovative solutions, reinforcing the platform’s use case and validating its model in the clinical trial ecosystem.
- Comprehensive Support: Opyl will provide trial feasibility assessments, predictive analytics, and competitor benchmarking to complement Avion’s operational excellence.
Under this agreement, Opyl and Avion will integrate the TrialKey platform into clinical trial planning and execution to achieve:
- Optimised trial design with AI-powered analytics.
- Improved site selection and participant recruitment strategies.
- Comprehensive, actionable reporting for enhanced decision-making.
The agreement will continue until terminated with 30 days’ written notice. During this period, Opyl will provide Avion with detailed reports and actionable insights for A$5,000 per report. Both parties have committed to working collaboratively to ensure seamless integration of the TrialKey platform into Avion’s operations.
“This partnership is a testament to the growing demand for TrialKey across the APAC region and beyond. Our continued collaborations with respected CROs, like Avion, demonstrate the industry’s confidence in our platform and its potential to transform clinical trials,” Opyl’s Chief Technology Officer, Damon Rasheed, said.
“Together, we’re driving a shift toward data-driven strategies that deliver faster, more efficient, and higher-quality trial outcomes.”
